Roche Holding Ltd · SIX:RO
Roche — Kepler Swiss Seminar 2025
21 slides from Roche's conference presentation, Mar 20, 2025
Slide 1: Slide 1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Rejuvenating the late-stage portfolio
Rejuvenating the late-stage portfolio Bruno Eschli | Head IR Roche Kepler Seminar, 20 March 2025
Slide 4: 2024: Group core operating profit
2024: Group core operating profit Core operating profit higher by +14% driven by higher sales and effective cost management 2024 2024 vs. 2023 CHFm abs. CER CER growth Sales 60,495 +4,107 7% Other revenue 1,900 +215 12% Cost of sales -15,398 -720 5% R&D -13,042 -128 1% SG&A -13,758 -625 5% OOI&E 626
Slide 5: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio 17 medicines achieved blockbuster status in 20241 Diagnostics: +8% base business growth +4% FY 2024 sales driven by Core Lab, Molecular Lab and (+8%)2 (CHFbn, YoY CER growth) Pathology Lab Phesgo: Conversion rate climbing to 46% 14.3 Alecensa: Geographic exp
Slide 6: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term Two NMEs launched in 2024: Itovebi in HR+ BC and PiaSky in PNH CHFm % of Pharma Sales2 30.0 56% 25.0 51% 44% 20.0 35% 15.0 1 10.0 5.0 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.0 FY 2021 FY 2022 FY 2023 FY 2024 Cotellic Alecensa
Slide 7: 2024: Young portfolio delivering strong growth
2024: Young portfolio delivering strong growth Polivy now one of 17 blockbusters in 2024* Vabysmo 68% Phesgo 62% Ocrevus 9% Hemlibra 12% Xolair 16% Polivy 39% Evrysdi 18% Elevidys n/a Columvi >500% Gazyva 16% Actemra / RoActemra 5% Alecensa 7% Enspryng 30% Xofluza 75% Perjeta 1% Tecentriq 0% US Luns
Slide 8: A solid base to deliver future growth
A solid base to deliver future growth Pipeline and business development to add significant upside potential illustrative Business development • BD to accelerate pipeline portfolio • In-house pipeline with upside Pharma pipeline potential • On-market Pharma portfolio to deliver growth until 2027 Sale
Slide 9: 2025 Pharma pipeline
2025 Pharma pipeline Peak sales potential of key assets New Molecular Entities (NME) giredestrant fenebrutinib vamikibart HR+ BC RMS, PPMS DME/UME Itovebi (inavolisib) Elevidys1 CT-388 Pi3Km BC DMD Obesity +/- T2D divarasib GYM 329 CT-868 • 7+ NMEs with CHF >3bn peak KRAS+ NSCLC, CRC SMA, FSHD T1D w
Slide 10: 2025 Pharma pipeline
2025 Pharma pipeline 12 key pivotal readouts including 4 NMEs expected New Molecular Entities (NME) 2 giredestrant Ph III persevERA 2 fenebrutinib Ph III FENhance 1/2 1 vamikibart Ph III HR+ BC Ph III evERA RMS, PPMS Ph III FENtrepid DME/UME SANDCAT/MEERKAT Itovebi (inavolisib) Elevidys CT-388 Pi3Km
Slide 11: 2025 Pharma pipeline
2025 Pharma pipeline 7 NMEs with Ph III enabling readouts expected New Molecular Entities (NME) giredestrant fenebrutinib vamikibart HR+ BC RMS, PPMS DME/UME Itovebi (inavolisib) Elevidys CT-388 Pi3Km BC DMD Obesity +/- T2D divarasib GYM 329 CT-868 KRAS+ NSCLC, CRC SMA, FSHD T1D with BMI ≥25 tiragol
Slide 12: Important launches in Diagnostics from 2024 onwards
Important launches in Diagnostics from 2024 onwards Diagnostics to deliver mid to high single digit growth in coming years Continuous glucose Next generation sequencing Core & Molecular Lab Mass spectrometry monitoring (CGM) (NGS) • Menu expansion driving growth, • First fully integrated and • Subcu
Slide 13: Overview of key strategic initiatives
Overview of key strategic initiatives Strategic review completed and in implementation Ten-Year Ambitions Group Strategy Group Strategy Digital Health Sustainability People & Culture Pharma Strategy Diagnostics Strategy Divisional Strategies R&D Excellence Formation of Near Patient Care Operational
Slide 14: Our new Pharma Strategy
Our new Pharma Strategy Providing clarity and intentional focus to leverage our scientific strengths and impact patients globally Where we play: Priority Therapeutic Areas How we succeed: Core capabilities Neurology Oncology/ Hematology Modalities & Devices Manufacturing Technologies Ophthalmology I
Slide 15: R&D Excellence: Our solutions
R&D Excellence: Our solutions We identified six solutions to achieve top quartile performance - with implementation ongoing Adopt a unified portfolio Transform our portfolio Access the best external framework management & governance innovation Introduce the ‘Bar’ to recognize assets Reconfigure end-
Slide 16: Strengthening our Pharma pipeline
Strengthening our Pharma pipeline Pipeline changes since Q2’23 siRNA targeting AGT in Allogeneic CAR-T in hypertension Onco/Heme, Immuno and Neuro 8 -8 24 Additions 81 4 -3 1 -5 • 14 Ph I additions from 3 -4 3 pRED/gRED/Chugai -9 5 -5 71 • 10 Ph I/Ph II NMEs acquired as Dual GLP-1/GIP RA in Anti-TL1
Slide 17: Roche's strengthened sustainability commitment
Roche’s strengthened sustainability commitment Our strategy contributes to the long-term success of Roche and society, focusing on six priorities Creating value for all stakeholders On track to meet our new Net Zero target Maximize access to our innovative medicines innovation Access to and diagnost
Slide 18: Roche's exceptional commitment to Global Health Security
Roche’s exceptional commitment to Global Health Security Diagnostics and Pharma taking a leading role to address antimicrobial resistance (AMR) crisis Diagnostics: Rapid identification of pathogens Pharma: First novel classes of antibiotics in 50 years 2 novel MoAs discovered by Roche/Genentech scie
Slide 19: 2025 guidance
2025 guidance LOE impact of CHF 1.2bn expected for 2025 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1At CER=Constant Exchange Rates (avg full year 2024); LOE=loss of exclusivity includ
Slide 20: IR events currently planned for 2025
IR events currently planned for 2025 Additional events driven by readouts Immunology/WCN Update on NGS Neurology Update Diagnostics Day Pharma Day 7 Feb 20 Feb 4 Apr 27 May 22 Sep 16:30 – 17:30 CET 20:30- 21:30 CET 16:00 – 17:30 CEST 14:00 - 16:30 CEST tbd Virtual event Virtual event Virtual event L
Slide 21: Doing now what patients need next
Doing now what patients need next